N-cyclopropyl-2-((2,5-dichloropyrimidin-4-yl)amino)benzamide | 953048-70-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-cyclopropyl-2-((2,5-dichloropyrimidin-4-yl)amino)benzamide
• 英文别名: 2-(2,5-dichloropyrimidin-4-ylamino)-N-cyclopropylbenzamide；N-cyclopropyl-2((2,5-dichloropyrimidin-4-yl)amino)benzamide；N-cyclopropyl-2-[(2,5-dichloropyrimidin-4-yl)amino]benzamide
• CAS: 953048-70-9
• 化学式: C₁₄H₁₂Cl₂N₄O
• 分子量: 323.181
• InChiKey: MSNKMYLFELIEAU-UHFFFAOYSA-N

物化性质

• 沸点：
  561.6±45.0 °C(predicted)
• 密度：
  1.48±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-cyclopropyl-2-((2,5-dichloropyrimidin-4-yl)amino)benzamide 、 对氨基苯甲酸 在 盐酸 作用下， 以 水 、 正丁醇 为溶剂， 以50%的产率得到4-(4-(2-(cyclopropylcarbamoyl)phenylamino)-5-chloropyrimidin-2-ylamino)-benzoic acid
  参考文献：
  名称：

  WO2008/79719

  摘要：

  公开号：
• 作为产物：
  描述：

  N-环丙基-2-硝基苯甲酰胺 在 甲醇 、 铁粉 、 氯化铵 、 N,N-二异丙基乙胺 作用下， 以 水 、 异丙醇 为溶剂， 反应 8.0h， 生成 N-cyclopropyl-2-((2,5-dichloropyrimidin-4-yl)amino)benzamide
  参考文献：
  名称：

  Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines

  摘要：

  A new class of pyrimidine derivatives were designed and synthesized as potential dual FAK and EGFR(T79)(0M) inhibitors using a fragment-based drug design strategy. This effort led to the identification of the two most active inhibitors, namely 9a and 9f, against both FAK (IC50, = 1.03 and 3.05 nM, respectively) and EGFR(T79)(0M) (IC50 = 3.89 and 7.13 nM, respectively) kinase activity. Moreover, most of these compounds also exhibited strong antiproliferative activity against the three evaluated FAK-overexpressing pancreatic cancer (PC) cells (AsPC-1, BxPC-3, Panc-1) and two drug-resistant cancer cell lines (breast cancer MCF-7/adr cells and lung cancer H1975 cells) at concentrations lower than 6.936 mu M. In addition, 9a was also effective in the in vivo assessment conducted in a FAK-driven human AsPC-1 cell xenograft mouse model. Overall, this study offers a new insight into the treatment of hard to treat cancers.

  DOI：

  10.1016/j.bioorg.2019.103408

文献信息

• [EN] SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE<br/>[FR] ANALOGUES DE N-PHÉNYLPYRIMIDINE-2-AMINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AXL KINASE
  申请人：UNIV UTAH RES FOUND

  公开号：WO2012135800A1

  公开（公告）日：2012-10-04

  In one aspect, the invention relates to substituted N-phenylpyrimidin-2-amine analogs, derivatives thereof, and related compounds, which are useful as inhibitors of Axl kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions for treating disorders associated with dysfunction of the Axl kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  该发明涉及替代的N-苯基嘧啶-2-胺类似物、其衍生物和相关化合物，它们可作为Axl激酶的抑制剂；合成这些化合物的方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与Axl激酶功能障碍相关的疾病的方法。本文摘要旨在作为在特定领域搜索的工具，并不意味着对本发明的限制。
• Pyrimidine Kinase Inhibitors
  申请人：Burdick Daniel J.

  公开号：US20080318989A1

  公开（公告）日：2008-12-25

  The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula (I) wherein ring A, X, Y, Z, R 1 , R 2 , R 3 , R 4 , m and n are as defined herein.

  本发明提供了新型激酶抑制剂，可用作治疗剂，例如在治疗恶性肿瘤方面，其中化合物具有一般式（I），其中环A、X、Y、Z、R1、R2、R3、R4、m和n如本文所定义。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。
• PYRIMIDINE KINASE INHIBITORS
  申请人：Krueger Elaine B.

  公开号：US20100144732A1

  公开（公告）日：2010-06-10

  The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein Q, X, Y, Z, R 1 , R 2 , R 4 , m and n are as defined herein.

  该发明提供了一种新型激酶抑制剂，可用作治疗剂，例如在治疗恶性肿瘤中，其中化合物具有一般式I，其中Q、X、Y、Z、R1、R2、R4、m和n如本文所定义。
• Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
  申请人：Ahmed Gulzar

  公开号：US20120165519A1

  公开（公告）日：2012-06-28

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。式I或II的化合物具有ALK和/或c-Met抑制活性，并可用于治疗增生性疾病。